雜志介紹

Investigational New Drugs雜志介紹

《Investigational New Drugs》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱研究性新藥，本刊主要出版、報道醫(yī)學-PHARMACOLOGY & PHARMACY領域的研究動態(tài)以及在該領域取得的各方面的經(jīng)驗和科研成果，介紹該領域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領域相關(guān)學科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為3，最新CiteScore 指數(shù)為7.6。

本刊近期中國學者發(fā)表的論文主要有：

• The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux

  Author: Qi, Defei; Dou, Yuanyuan; Zhang, Wenke; Wang, Mengqing; Li, Yingying; Zhang, Mingzhu; Qin, Jia; Cao, Jinlan; Fang, Dong; Ma, Jing; Yang, Wei; Xie, Songqiang; Sun, Hua

• Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

  Author: Qian, Kun; Chen, Qi-Rui; He, Ming; Wang, Zi-Tong; Liu, Yu; Liang, Hua-Gang; Su, Zhi-Yong; Cui, Yu-Shang; Liu, Li-Jun; Zhang, Yi

• Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions

  Author: Liu, Zhengzhi; Xu, Zhongnan; Gao, Zhenyue; Ren, Qing; Chang, Tianying; Xue, Jinling; Yang, Haimiao

• Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China

  Author: Hou, Helei; Wang, Yongjie; Sun, Dantong; Zhu, Jingjuan; Jiang, Man; Zhang, Xuchen; Zhou, Na; Zhang, Chuantao; Li, Tianjun; Zhang, Xiaochun

英文介紹

Investigational New Drugs雜志英文介紹

The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.